中文 | English
Return
Total: 10 , 1/1
Show Home Prev Next End page: GO
Author:( Jiangjiang HU)

1.Analysis on the Impact of Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ : IgG Fc Fusion Protein on Medical Insurance Budget

Yabing ZHANG ; Shanlian HU ; Jiangjiang HE

Chinese Health Economics 2017;36(3):56-58

2.Development experiences of integrated healthcare in England:A case in Oxfordshire

Chunyan XIE ; Shanlian HU ; Jiangjiang HE

Chinese Journal of Health Policy 2014;(9):72-78

3.Analysis on the operation of personal saving accounts for Urban Employees' Basic Medical In-surance in Shanghai

Linan WANG ; Min ZHANG ; Jiangjiang HE ; Shanlian HU

Chinese Journal of Health Policy 2017;10(2):44-49

4.Exploration study on monitoring and evaluation of health system reform in Shanghai

Hansheng DING ; Jiangjiang HE ; Wen CHEN ; Guangwen GAO ; Shanlian HU

Chinese Journal of Hospital Administration 2012;28(1):5-8

5.Progress and bottlenecks of family doctor system in Shanghai

Jiangjiang HE ; Yinghua YANG ; Tianye ZHANG ; Chunyan XIE ; Zhenqing TANG ; Meng CAO ; Hongwei LIU ; Shanlian HU

Chinese Journal of Health Policy 2014;(9):17-21

6.Expression of NonO protein during murine erythroleukemia cell differentiation induced by sodium butyrate

Tingting SANG ; Jiangjiang HU ; Jianyou XUE ; Wulin QI ; Fukun ZHAO ; Shifu ZHANG

Acta Anatomica Sinica 2014;(4):516-520

7.Comprehensive evaluation of community health services in Shanghai

Jiangjiang HE ; Heng ZHONG ; Heping WAN ; Yingyao CHEN ; Tianye ZHANG ; Chunyan XIE ; Qiongwei HU ; Guojun HUANG ; Xiaoxiao LI ; Shanlian HU

Chinese Journal of Hospital Administration 2015;(8):633-637

8.Cost-utility Analysis of Recombinant Human Type Ⅱ Tumor Necrosis Factor Receptor-antibody Fusion Protein in the Treatment of Rheumatoid Arthritis

Yabing ZHANG ; Shanlian HU ; Jiangjiang HE

China Pharmacy 2018;29(5):662-666

9.Budget Effect Analysis of Ivabradine in the Treatment of Heart Failure on Medical Insurance Fund in China

Shanlian HU ; Jiangjiang HE ; Tian SUN ; Yan YANG ; Qi KANG

China Pharmacy 2019;30(8):1094-1099

10.Study Feasibility of Multi-payment for Drugs for Rare Diseases ——Taking Gaucher’s Disease in Qingdao as Example

Yan YANG ; Jiangjiang HE ; Yueqiang WANG ; Qi KANG ; Shanlian HU

China Pharmacy 2019;30(19):2593-2597

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 10 , 1/1 Show Home Prev Next End page: GO